NYSE: NVONovo Nordisk A S Stock
$84.43-0.02 (-0.02%)
Updated Jun 14, 2021
NVO Price
$84.43
Fair Value Price
N/A
Market Cap
$198.41B
52 Week Low
$63.22
52 Week High
$84.94
P/E
28.37x
P/B
21.03x
P/S
7.87x
PEG
3.64x
Dividend Yield
1.74%
Revenue
$20.46B
Earnings
$6.80B
Gross Margin
83.2%
Operating Margin
44.27%
Profit Margin
33.8%
Debt to Equity
1.42
Operating Cash Flow
$8B
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
44
Industry average
Reasons for this score
NVO ($84.43) is trading below its intrinsic value of $130.98, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
NVO is poor value based on its earnings relative to its share price (28.37x), compared to the US market average (27.51x)
Valuation
NVO is good value based on its earnings relative to its share price (28.37x), compared to the US Biotechnology industry average (121.28x)
Valuation
NVO News
Valuation
NVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
28.37x
Industry
121.28x
Market
27.51x
NVO is poor value based on its earnings relative to its share price (28.37x), compared to the US market average (27.51x)
Valuation
NVO is good value based on its earnings relative to its share price (28.37x), compared to the US Biotechnology industry average (121.28x)
Valuation
NVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
21.03x
Industry
6.45x
NVO is poor value based on its book value relative to its share price (21.03x), compared to the US Biotechnology industry average (6.45x)
Valuation
NVO price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVO is poor value relative to its rate of earnings growth, measured by PEG ratio (3.64x)
Valuation
NVO's financial health
Profit margin
Revenue
$5.4B
Net Income
$2.0B
Profit Margin
37.3%
NVO's Earnings (EBIT) of $9.06B can safely cover interest payments on company debt ($1.56B)
Financials
NVO's profit margin has increased (+1.9%) in the last year from (31.9%) to (33.8%)
Financials
Assets to liabilities
Assets
$22.4B
Liabilities
$13.2B
Debt to equity
0.17
NVO's short-term liabilities ($11.67B) exceed its short-term assets ($9.90B)
Financials
NVO's short-term assets ($9.90B) exceed its long-term liabilities ($1.69B)
Financials
NVO's debt has increased relative to shareholder equity (1.42), over the past 5 years ago (1.21)
Financials
NVO's debt to equity ratio (1.42) is considered high
Financials
Cash flow
Operating
$1.8B
Investing
-$552.5M
Financing
-$2.3B
NVO's operating cash flow ($8.58B) is sufficient to service the company's debt ($1.56B)
Financials
Novo Nordisk A S Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.